ArticleCureus2025
Late Metastatic Recurrence of Merkel Cell Carcinoma Nine Years After the Primary Diagnosis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer of neuroendocrine origin that has been known to recur and metastasize within the first three years of initial diagnosis. MCC is typically diagnosed with clinicopathologic correlation of a red-purple nodule or flesh colored papule on sun-damaged skin and characteristic immunohistochemical staining. We present a case of a 66-year-old White man who was found to have metastatic MCC over nine years after the initial stage one tumor was diagnosed and treated with Mohs micrographic surgery (MMS) and radiation therapy. This case highlights the importance of defining prognostic biomarkers for each patient with MCC and consideration of extended surveillance beyond the current recommended three years. Clinicians should also be attentive when counseling patients to explain that the risk of late metastasis, although low, is still possible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.